In addition, two other clinical trials demonstrated the non-inferiority of guselkumab to anti-IL-17 secukinumab and ixekizumab in achieving skin clearance in adult patients with plaque psoriasis [48,49]. Here, IL17A is linked to psoriasis vulgaris.